Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.
Alcohol compositions are desirable hand and skincare products. They are effective against a wide range of microorganisms such as gram positive and gram negative bacteria and fungi. And they are able to kill microorganisms faster than other antimicrobial products. Alcohol antimicrobial products are available as water thin liquids, gels, emulsions, and aerosol foams. Commercially available aerosol alcohol foams, such as QUIKCARE™, commercially available from Ecolab Inc. (St. Paul, Minn.) rely on propellants to generate the foam. Propellants are needed because the surface tension of alcohol is too low for most surfactants to be able to generate foam and sustain it at atmospheric pressure. But, aerosol products are less desirable because of their inherent drawbacks of not being able to visually monitor the product contents in the container, the additional packaging complexity, and cost. It is desirable to move away from aerosol cans and aerosol propellants to less complex packaging and chemistry that allows a customer to see the product contents in the container while maintaining the aesthetic benefits of a foaming product. It is against this background that the present invention has been made.
Surprisingly, it has been discovered that PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant are especially effective at generating foam in alcohol products at atmospheric pressure in transparent or translucent, non-aerosol packaging. The PEG-8 to PEG-12 linear dimethicone surfactants are more effective than dimethicone surfactants with the same PEG chain length but a different polymer architecture.
In some embodiments, the invention relates to a non-aerosol antimicrobial composition with a PEG-8 to PEG-12 linear dimethicone surfactant, an alcohol, and water, where the dimethicone can generate an average foam height of greater than 20 mm without needing more than 5% of additional surfactant. In some embodiments, the invention relates to a non-aerosol antimicrobial composition with a PEG-10 linear dimethicone surfactant, an alcohol, and water, where the dimethicone can generate an average foam height of greater than 20 mm without needing more than 5% of additional surfactant. In some embodiments, the composition also contains additional materials such as skin conditioners, terpenoids, chelating agents, and preservatives.
These and other embodiments will be apparent to those of skill in the art and others in view of the following detailed description of some embodiments. It should be understood, however, that this summary, and the detailed description illustrate only some examples of various embodiments, and are not intended to be limiting to the invention as claimed.
As discussed above, the invention generally relates to foaming alcohol compositions with PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.
PEG-8 to PEG-12 Linear Dimethicone Surfactants
Surprisingly, it has been discovered that PEG-8 to PEG-12 linear dimethicone surfactants, and in particular PEG-10 linear dimethicone surfactant, are more effective at generating and stabilizing foam in alcohol compositions than dimethicone surfactants with the same PEG chain length but a different polymer architecture.
More particularly it has been discovered that linear block copolymers of PEG with polydimethylsiloxane (specifically with INCI names of PEG-8 dimethicone, PEG-10 dimethicone, and PEG-12 dimethicone) can produce a sufficient foam height to be used as the primary foaming component of a non-aerosol foaming alcohol compositions, which is not the case for copolymers with the same INCI names but different polymer architectures. For example, polymers with pendant PEG groups or other highly branched polymer structures, will not produce sufficient foam to be used as a primary foaming surfactant. In the case of PEG dimethicone copolymers, linear block copolymers refer to when polyethylene glycol chain units are attached to the terminal ends of the linear polydimethylsiloxane backbone:
where R═CH3 or CH2CH3, m=4-20 on average, y=1-5 and n=8-12 on average.
Pendant copolymers refer to linear polydimethylsiloxane polymers with PEG groups attached along the polydimethylsiloxane backbone and may or may not be attached to the terminal chain ends of the polydimethylsiloxane. Such pendant copolymers are often referred to as having a comb or comb-like structure such as:
where R is independently=CH3, CH2CH3, or an ethoxylated alkyl chain (for example CH2CH2CH2O(CH2CH2O)nH) attached directly to the silicone end group and a=a repeating silicone group.
Some examples of commercially available PEG-8 to PEG-12 linear dimethicone surfactants include Silsoft 810 (PEG-8) and Silsoft 870 (PEG-12) from Momentive Performance Materials, and Silsurf DI-1010 (PEG-10) from Siltech. In some embodiments, the dimethicone surfactant is preferably a PEG-10 linear dimethicone surfactant.
The dimethicone surfactant can be present in the alcohol composition from about 0.5 to about 10 wt. %, from about 1.0 to about 7 wt. % and from about 2 to about 5 wt. %.
Alcohol
In addition to water, the composition includes an alcohol. The alcohol is preferably a lower chain alcohol such as a C2-C4 alcohol. Examples of suitable alcohols include ethanol, propanols, such as isopropanol and n-propanol, and butanols. The alcohol is preferably ethanol.
The composition may contain one alcohol, or a mixture of two or more alcohols. The alcohol is preferably present in the composition in an amount of active alcohol from about 50 to about 90 wt. %, from about 54 to about 85 wt. %, and from about 60 to about 80 wt. %.
Skin Conditioner
The composition may optionally include at least one skin conditioner such as an emollient, humectant, occlusive agent, or other moisturizer to provide moisturization, skin softening, skin barrier maintenance, anti-irritation, or other skin health benefits. Some non-limiting examples of emollients include alkyl benzoate, myristyl myristate, cetyl myristate, glyceryl dioleate, methyl laurate, PPG-9 laurate, lauryl lacylate allantoin, octyl palmitate, lanolin, propylene glycol, butylenes glycol, ethylene glycol monobutyl ether, glycerine, fatty acids, natural oils such as almond, mineral, canola, sesame, soybean, wheat germ, corn, peanut and olive oil, isopropyl myristate, myristyl alcohol, aloe vera, hydrolyzed silk protein, Vitamin E, stearyl alcohol, isopropyl palmitate, sorbitol, amino acid complexes, hydrolyzed plant proteins, and polyethylene glycol. Some non-limiting examples of humectants include hydroxyethyl urea, agarose, urea, sodium PCA, arginine PCA, fructose, glucose, glutamic acid, glycerine, honey, lactose, maltose, polyethylene glycol, sorbitol and mixtures thereof. Some non-limiting examples of occlusive agents include petrolatum, shea butter, avocado oil, balm mint oil, cod liver oil, mineral oil, trimyristin, stearyl stearate, synthetic wax, or mixtures thereof. Some non-limiting examples of other moisturizers include ethyl hexylglycerin, cholesterol, cystine, hyaluronic acid, keratin, lecithin, egg yolk, glycine, PPG-12, polyquaternium polymers such as polyquaternium-11, benentrimonium chloride, dihydroxypropyl PEG-5 linoleammonium chloride, glycerol oleate, PEG-7 glyceryl cocoate, cocoglucoside, PEG-200 hydrogenated glyceryl palmate, panthenol, retinol, salicylic acid, vegetable oil, methyl gluceth-10, methyl gluceth-20, ethoxylated derivatives of skin conditioners such as glycereth-26 and ethoxylated shea butter, and mixtures thereof. Finally, some non-limiting examples of anti-irritants include bisabolol and panthenol.
A person skilled in the art will recognize the different strengths of different skin conditioners and formulate accordingly. In some embodiments, the skin conditioner is preferably present in the composition in an amount from about 0.01 to about 20 wt. %, from about 0.05 to about 15 wt. %, and from about 0.1 to about 10 wt. %.
Terpenoid
The composition may optionally include a terpenoid. Terpenoids are defined as materials with molecular structures containing carbon backbones made up of isoprene (2-methylbuta-1,3-diene) units. Isoprene contains five carbon atoms and therefore, the number of carbon atoms in any terpenoid is a multiple of five. It is believed that terpenoids assist in promoting the uptake of antimicrobial compounds and preservatives by cells of bacteria and fungi, thereby increasing the efficacy of the antimicrobial compound or preservative. See U.S. Pat. No. 6,319,958 and DE 195 23 320 which are incorporated by reference in their entirety. Some non-limiting examples of terpenoids include α-terpinene, cineole, citral, citronellal, citronellol, farnesol, geraniol, limonene, linalool, methone, nerolidol, terpineol, camphene, menthone, myrcene, nerol, tetrayhydrogeraniol, tetrahydrolinalool, apritone, and bisabolol. The terpenoid is preferably farnesol, nerolidol, bisabolol, or apritone.
The terpenoid is preferably present in the composition in an amount from about 0.005 to about 5 wt. %, from about 0.05 to about 2.5 wt. %, and from about 0.1 to about 1.5 wt. %.
Chelating Agent
The composition may optionally include a chelating agent. Examples of chelating agents include phosphonic acid and phosphonates, phosphates, aminocarboxylates and their derivatives, pyrophosphates, ethylenediamine and ethylenetriamine derivatives, hydroxyacids, and mono-, di-, and tri-carboxylates and their corresponding acids. Other chelating agents include nitroloacetates and their derivatives, and mixtures thereof. Examples of aminocarboxylates include amino acetates and salts thereof. Suitable amino acetates include: N-hydroxyethylaminodiacetic acid; hydroxyethylenediaminetetraacetic acid; nitrilotriacetic acid (NTA); ethylenediaminetetraacetic acid (EDTA); N-hydroxyethyl-ethylenediaminetriacetic acid (HEDTA); tetrasodium ethylenediaminetetraacetic acid (EDTA); diethylenetriaminepentaacetic acid (DTPA); and alanine-N,N-diacetic acid; n-hydroxyethyliminodiacetic acid; and the like; their alkali metal salts; and mixtures thereof. Suitable aminophosphates include nitrilotrismethylene phosphates and other aminophosphates with alkyl or alkaline groups with less than 8 carbon atoms. Exemplary polycarboxylates iminodisuccinic acids (IDS), sodium polyacrylates, citric acid, gluconic acid, oxalic acid, salts thereof, mixtures thereof, and the like. Additional polycarboxylates include citric or citrate-type chelating agents, polymeric polycarboxylate, and acrylic or polyacrylic acid-type chelating agents. Additional chelating agents include polyaspartic acid or co-condensates of aspartic acid with other amino acids, C4-C25-mono-or-dicarboxylic acids and C4-C25-mono-or-diamines. Exemplary polymeric polycarboxylates include polyacrylic acid, maleic/olefin copolymer, acrylic/maleic copolymer, polymethacrylic acid, acrylic acid-methacrylic acid copolymers, hydrolyzed polyacrylamide, hydrolyzed polymethacrylamide, hydrolyzed polyamide-methacrylamide copolymers, hydrolyzed polyacrylonitrile, hydrolyzed polymethacrylonitrile, hydrolyzed acrylonitrile-methacrylonitrile copolymers, and the like.
The chelating agent may be present in an amount from about 0.01 to about 5 wt. %, from about 0.05 to about 3 wt. %, and from about 0.1 to about 1.5 wt. %.
Preservatives
The composition may optionally include a preservative. Generally, preservatives fall into specific classes including phenolics, halogen compounds, quaternary ammonium compounds, metal derivatives, amines, alkanolamines, nitro derivatives, biguanides, analides, organosulfur and sulfur-nitrogen compounds, alkyl parabens, and miscellaneous compounds. Some non-limiting examples of phenolic antimicrobial agents include pentachlorophenol, orthophenylphenol, chloroxylenol, p-chloro-m-cresol, p-chlorophenol, chlorothymol, m-cresol, o-cresol, p-cresol, isopropyl cresols, mixed cresols, phenoxyethanol, phenoxyethylparaben, phenoxyisopropanol, phenyl paraben, resorcinol, and derivatives thereof. Some non-limiting examples of halogen compounds include trichlorohydroxy diphenyl ether (Triclosan), sodium trichloroisocyanurate, sodium dichloroisocyanurate, iodine-poly(vinylpyrolidin-onen) complexes, and bromine compounds such as 2-bromo-2-nitropropane-1,3-diol, and derivatives thereof. Some non-limiting examples of quaternary ammonium compounds include benzalkonium chloride, benzethonium chloride, behentrimonium chloride, cetrimonium chloride, and derivatives thereof. Some non-limiting examples of amines and nitro containing compounds include hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine, dithiocarbamates such as sodium dimethyldithiocarbamate, and derivatives thereof. Some non-limiting examples of biguanides include polyaminopropyl biguanide and chlorhexidine gluconate. Some non-limiting examples of alkyl parabens include methyl, ethyl, propyl and butyl parabens.
The preservative is preferably present in the composition in an amount from about 0 to about 3 wt. %, from about 0.1 to about 2 wt. %, and from about 0.2 to about 1 wt. %.
Thickener
The composition may optionally include a thickener. Exemplary thickeners include (1) cellulosic thickeners and their derivatives, (2) natural gums, (3) starches, (4) stearates, and (5) fatty acid alcohols. Some non-limiting examples of cellulosic thickeners include carboxymethyl hydroxyethylcellulose, cellulose, hydroxybutyl methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methyl cellulose, methylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and the like. Some non-limiting examples of natural gums include acacia, calcium carrageenan, guar, gelatin, guar gum, hydroxypropyl guar, karaya gum, kelp, locust bean gum, pectin, sodium carrageenan, tragacanth gum, xanthan gum, and the like. Some non-limiting examples of starches include oat flour, potato starch, wheat flour, wheat starch, and the like. Some non-limiting examples of stearates include PEG-150 distearate, methoxy PEG-22/dodecyl glycol copolymer, and the like. Some non-limiting examples of fatty acid alcohols include caprylic alcohol, cetearyl alcohol, lauryl alcohol, oleyl alcohol, palm kernel alcohol, and the like.
The amount of thickener in the composition depends on the desired viscosity of the composition. The composition preferably has a viscosity low enough to pump through a foamer such as an Airspray foamer and allow foaming.
Additional Functional Ingredients
Additional functional ingredients may be used to improve the effectiveness of the composition. Some non-limiting examples of such additional functional ingredients include skin feel improvers, antioxidants, fragrances, dyes, and mixtures thereof.
Skin Feel Improver
The composition may optionally include a skin feel improver for enhancing the “feel” of the composition on a user's skin or hands. For example, it may be undesirable for a composition to have a scaly or gritty texture when applied to a user's skin or after the multiple applications of the composition. Some non-limiting examples of skin feel improvers include silicone copolymers such as amodimethicone, cyclomethicone, bis-PEG/PPG-20/20 dimethicone, and stearoxytrimethylsilane, naturally occurring or synthetic fatty acid esters or ethers, and polyalkylene glycols.
If a skin feel improver is included, it is preferably present in the composition in an amount from about 0.001 to about 5 wt. %, from about 0.01 to about 3 wt. %, and from about 0.1 to about 2 wt. %.
Antioxidant
The composition may optionally include an antioxidant for improved skin condition through the removal of free radicals, and improved product stability. Some non-limiting examples of antioxidants include retinol and retinol derivatives, ascorbic acid and ascorbic acid derivatives, BHA, BHT, betacarotene, cysteine, erythorbic acid, hydroquinone, tocopherol and tocopherol derivatives, and the like.
If an antioxidant is included, it is preferably present in the composition in an amount from about 0.001 to about 2 wt. %, from about 0.01 to about 1 wt. %, and from about 0.05 to about 0.5 wt. %.
Fragrance
The composition may optionally include a fragrance. Examples of possible fragrances include natural oils or naturally derived materials, and synthetic fragrances such as hydrocarbons, alcohols, aldehydes, ketones, esters, lactones, ethers, nitriles, and polyfunctionals. Non-limiting examples of natural oils include the following: basil (Ocimum basilicum) oil, bay (Pimento acris) oil, bee balm (Monarda didyma) oil, bergamot (Citrus aurantium bergamia) oil, cardamom (Elettaria cardamomum) oil, cedarwood (Cedrus atlantica) oil, chamomile (Anthemis nobilis) oil, cinnamon (Cinnamomum cassia) oil, citronella (Cymbopogon nardus) oil, clary (Salvia sclarea) oil, clove (Eugenia caryophyllus) oil, cloveleaf (Eufenia caryophyllus) oil, Cyperus esculentus oil, cypress (Cupressus sempervirens) oil, Eucalyptus citriodora oil, geranium maculatum oil, ginger (Zingiber officinale) oil, grapefruit (Citrus grandis) oil, hazel (Corylus avellana) nut oil, jasmine (Jasminum officinale) oil, Juniperus communis oil, Juniperus oxycedrus tar, Juniperus virginiana oil, kiwi (Actinidia chinensis) water, lavandin (Lavandula hybrida) oil, lavender (Lavandula angustifolia) oil, lavender (Lavandula angustifolia) water, lemon (Citrus medico limonum) oil, lemongrass (Cymbopogon schoenanthus) oil, lime (Citrus aurantifolia) oil, linden (Tilia cordata) oil, linden (Tilia cordata) water, mandarin orange (Citrus nobilis) oil, nutmeg (Myristica fragrans) oil, orange (Citrus aurantium dulcis) flower oil, orange (Citrus aurantium dulcis) oil, orange (Citrus aurantium dulcis) water, patchouli (Pogostemon cablin) oil, peppermint (Menthe piperita) oil, peppermint (Menthe peperita) water, rosemary (Rosmarinus officinalis) oil, rose oil, rose (Rosa damascena) extract, rose (Rosa multiflora) extract, rosewood (Aniba rosaeodora) extract, sage (Salvia officinalis) oil, sandalwood (Santalum album) oil, spearmint (Menthe viridis) oil, tea tree (Melaleuca alternifolia) oil, and ylang ylang (Cananga odorata) oil. Some non-limiting examples of synthetic hydrocarbon fragrances include caryophyllene, β-farnesene, limonene, α-pinene, and β-pinene. Some non-limiting examples of synthetic alcohol fragrances include bacdanol, citronellol, linalool, phenethyl alcohol, and α-terpineol (R═H). Some non-limiting examples of synthetic aldehyde fragrances include 2-methyl undecanal, citral, hexyl cinnamic aldehyde, isocycolcitral, lilial, and 10-undecenal. Some non-limiting examples of synthetic ketone fragrances include cashmeran, α-ionone, isocyclemone E, koavone, muscone, and tonalide. Some non-limiting examples of synethetic ester fragrances include benzyl acetate, 4-t-butylcyclohexyl acetate (cis and trans), cedryl acetate, cyclacet, isobornyl acetate, and α-terpinyl acetate (R=acetyl). Some non-limiting examples of synthetic lactone fragrances include coumarin, jasmine lactone, muskalactone, and peach aldehyde. Some non-limiting examples of synthetic ether fragrances include ambroxan, anther, and galaxolide. Some non-limiting examples of synthetic nitrile fragrances include cinnamonitrile and gernonitrile. Finally, some non-limiting examples of synthetic polyfunctional fragrances include amyl salicylate, isoeugenol, hedione, heliotropine, lyral, and vanillin.
The composition may include a mixture of fragrances including a mixture of natural and synthetic fragrances. The fragrance can be present in a composition in an amount up to about 5 wt. %, preferably from about 0.01 to about 3 wt. %, from about 0.05 to about 1 wt. %, and from about 0.1 to about 0.2 wt. %.
Dye
The composition may optionally include a dye. Examples of dyes include any water soluble or product soluble dye, any FD&C or D&C approved dye. The dye can be present in an amount up to about 0.5 wt. %, preferably from about 0.00001 to about 0.1 wt. %, from about 0.0001 to about 0.01 wt. %, and from about 0.0001 to about 0.0005 wt. %.
Compositions
The non-aerosol alcohol compositions are especially useful as hand and skincare compositions for reducing microorganisms on the target surface.
In some embodiments, the composition includes less than about 10%, less than about 5% or less than about 1% any additional surfactant. The use of additional surfactant may be limited because the selected dimethicone surfactants are capable of producing and maintaining foam without needing help from additional surfactants.
In some embodiments, the composition includes less than about 10%, less than about 5% or less than about 1% any additional silicone materials besides the PEG-8, PEG-10, or PEG-12 linear dimethicone surfactant.
In some embodiments, the composition includes less than about 10%, less than about 5% or less than about 1% any foam stabilizers.
In some embodiments, the composition may be free or substantially free of additional surfactant, additional silicone material, or foam stabilizer. In some embodiments, the composition may be free or substantially free of a fluorosurfactant.
The composition may be provided as a water thin liquid, structured liquid or emulsion. The composition is preferably provided as a ready to use composition, meaning that the composition is provided in a way that can be applied without needing to dilute it first.
Packaging and Dispensers
The composition may be provided in various packaging sizes. Examples of packaging sizes include 1.5 oz, 500 ml and 1 liter bottles. The selected packaging preferably has a pump head foamer. Examples of commercially available pump head foamers include the F2 foamer from Rexam PLC (London, England, formerly Airspray), and the RF-17 Palm Foamer from Rieke Corporation (Auburn, Ind.).
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure.
Weight percent, percent by weight, % by weight, wt %, and the like are synonyms that refer to the concentration of a substance as the weight of that substance divided by the weight of the composition and multiplied by 100.
The recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4 and 5).
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing “a compound” includes a mixture of two or more compounds. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
For a more complete understanding of the invention, the following examples are given to illustrate some embodiment. These examples and experiments are to be understood as illustrative and not limiting. All parts are by weight, except where it is contrarily indicated.
Example 1 shows various silicone surfactants and their ability to generate a stable foam. The foaming ability of the silicone surfactants was evaluated using the following foam height screening procedure.
Stock Solution Preparation:
A solution consisting of 75.6% Ethanol SDA 40B (190 proof, 99.5% Active) and 24.4% water was prepared.
Sample Preparation:
To a 20 mL vial, approximately 0.35 g of silicone surfactant and 9.65 g Stock solution were weighed. The solution was then mixed until a homogeneous solution was achieved.
Foam Height Screening:
To screen the foam height of each solution, a small portion (˜1 mL) of the prepared solution was placed into a 2 oz bottle with an Airspray foaming pump head, rinsed around, and discarded. After the rinsing of the bottle, the remaining contents of the sample preparation were then transferred into the 2 oz bottle with an Airspray foaming pump head. The foaming pump head was primed until liquid or foam was generated through the foamer head. Up to three additional pumps were performed to ensure that the initial solution had been evacuated through the pump. After priming the pump, three additional pumps were performed, directing the material into a 20 mL glass vial. The height of the foam above the liquid line was immediately measured in millimeters using a ruler. The process was repeated one additional time and the two foam height measurements were averaged. The results are shown in Table 1.
Table 1 shows that only the linear dimethicones are able to produce a foam height greater than 20 mm. Exemplary dimethicone surfactants in Table 1 with a foam height of greater than 20 mm include Silsurf DI-1010 from Siltech, Silsoft 810 from GE Silicone, and Silsoft 870 from Momentive.
Example 2 determined the effect of dimethicone surfactant concentration on the foam height. For this example, the foam height was measured using the following test:
Stock Solution Preparation:
A solution was prepared with the following formula:
The following amounts were added to 60 mL jars. The silicone surfactants used were Silsurf DI-1010, Silsoft 810, and Silsoft 870.
Sample Preparation:
To a 60 mL jar,
Foam Height Screening:
To screen the foam height of each solution, a small portion (˜1 mL) of the prepared solution was used to rinse a 2 oz bottle with an Airspray foaming pump head and discarded. After rinsing the bottle, the remaining contents of the sample preparation were then transferred into the 2 oz bottle with an Airspray foaming pump head. The foaming pump head was primed until liquid or foam was generated through the foamer head. Up to three additional pumps were performed to ensure that the rinse solution had been evacuated through the pump. After priming the pump, three additional pumps were performed, directing the material into a 20 mL glass vial. The height of the foam above the liquid line was immediately measured in millimeters using a ruler. The process was repeated and the two foam height measurements were averaged. The results are shown in Table 2.
Table 2 shows that 0.5-1 gram of silicone surfactant (samples 2 and 3) is preferred in order to generate 20 mm of foam.
The foregoing summary, detailed description, and examples provide a sound basis for understanding the invention, and some specific example embodiments of the invention. Since the invention can comprise a variety of embodiments, the above information is not intended to be limiting. The invention resides in the claims.
This application is a Continuation application of U.S. Ser. No. 14/496,468 filed Sep. 25, 2014, now U.S. Pat. No. 9,414,586 issued on Aug. 16, 2016, which is a Continuation application of U.S. Ser. No. 14/084,726 filed Nov. 20, 2013, now U.S. Pat. No. 8,940,797, which is a Continuation application of U.S. Ser. No. 13/926,051 filed Jun. 25, 2013, now U.S. Pat. No. 8,658,701 issued Feb. 25, 2014, which is a Continuation application of U.S. Ser. No. 13/742,996 filed Jan. 16, 2013, now U.S. Pat. No. 8,530,524 issued on Sep. 10, 2013, which is a Continuation application of U.S. Ser. No. 13/223,419 filed Sep. 1, 2011, now U.S. Pat. No. 8,383,686 issued on Feb. 26, 2013, which is a Continuation application of U.S. Ser. No. 12/787,624, filed May 26, 2010, now U.S. Pat. No. 8,058,315 issued on Nov. 15, 2011, which is a Continuation of U.S. Ser. No. 12/179,382 filed Jul. 24, 2008, now U.S. Pat. No. 7,842,725, issued Nov. 30, 2010, herein incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2096837 | Baker | Oct 1937 | A |
2198354 | Tjaarda | Apr 1940 | A |
2301989 | Zamborsky | Nov 1942 | A |
2367719 | Gallay | Jan 1945 | A |
2396742 | Milliken | Mar 1946 | A |
2410796 | Newbery et al. | Nov 1946 | A |
2436414 | Arnemo | Feb 1948 | A |
2444870 | Clifford | Jul 1948 | A |
2472564 | Britten, Jr. | Jun 1949 | A |
2487270 | Peterson et al. | Nov 1949 | A |
2516816 | Wagner et al. | Jul 1950 | A |
2523207 | Fowler et al. | Sep 1950 | A |
2533950 | McCormick | Dec 1950 | A |
2539987 | Burger | Jan 1951 | A |
2562329 | O'Brien | Jul 1951 | A |
2572107 | Butin | Oct 1951 | A |
2595025 | Tripplehorn | Apr 1952 | A |
2596994 | Haberland | May 1952 | A |
2600854 | Cross | Jun 1952 | A |
2647311 | Arden | Aug 1953 | A |
3787566 | Gauvrean | Jan 1974 | A |
4096240 | Mathur | Jun 1978 | A |
4220665 | Klein | Sep 1980 | A |
4258052 | Yu et al. | Mar 1981 | A |
4336151 | Like et al. | Jun 1982 | A |
4511486 | Shah | Apr 1985 | A |
4714568 | Hurnik et al. | Dec 1987 | A |
4725609 | Kull, Jr. et al. | Feb 1988 | A |
4758599 | Minetti | Jul 1988 | A |
4857302 | Decker, Jr. et al. | Aug 1989 | A |
5015228 | Columbus et al. | May 1991 | A |
5047249 | Rothman et al. | Sep 1991 | A |
5073371 | Turner et al. | Dec 1991 | A |
5167950 | Lins | Dec 1992 | A |
D338585 | Bell et al. | Aug 1993 | S |
5250290 | Giacomoni et al. | Oct 1993 | A |
5254331 | Mausner | Oct 1993 | A |
5256401 | Duckenfield et al. | Oct 1993 | A |
5265772 | Bartasevich et al. | Nov 1993 | A |
5266598 | Ninomiya et al. | Nov 1993 | A |
D343751 | Bell et al. | Feb 1994 | S |
D346332 | Kanfer et al. | Apr 1994 | S |
5336497 | Guerrero et al. | Aug 1994 | A |
5370267 | Schroeder | Dec 1994 | A |
5441178 | Wysocki | Aug 1995 | A |
5443236 | Bell et al. | Aug 1995 | A |
5449137 | Bell et al. | Sep 1995 | A |
5462688 | Lippman et al. | Oct 1995 | A |
D365509 | Bell et al. | Dec 1995 | S |
D365518 | Wysocki | Dec 1995 | S |
D365755 | Kanfer et al. | Jan 1996 | S |
5523014 | Dolan et al. | Jun 1996 | A |
5558453 | Bell et al. | Sep 1996 | A |
5587358 | Sukigara et al. | Dec 1996 | A |
5625659 | Sears | Apr 1997 | A |
5629006 | Hoang et al. | May 1997 | A |
5635462 | Fendler et al. | Jun 1997 | A |
D383001 | Bell et al. | Sep 1997 | S |
D385795 | Wysocki et al. | Nov 1997 | S |
5718353 | Kanfer et al. | Feb 1998 | A |
5719113 | Fendler et al. | Feb 1998 | A |
D392136 | Ross et al. | Mar 1998 | S |
5725131 | Bell et al. | Mar 1998 | A |
D400799 | Bell et al. | Nov 1998 | S |
5833998 | Biedermann et al. | Nov 1998 | A |
5902778 | Hartmann et al. | May 1999 | A |
D411456 | Mast et al. | Jun 1999 | S |
5939082 | Oblong et al. | Aug 1999 | A |
5944227 | Schroeder et al. | Aug 1999 | A |
D415343 | Maddox | Oct 1999 | S |
5962482 | Bissett | Oct 1999 | A |
5968528 | Deckner et al. | Oct 1999 | A |
5972356 | Peffly et al. | Oct 1999 | A |
D416417 | Ross et al. | Nov 1999 | S |
5980921 | Biedermann et al. | Nov 1999 | A |
5989523 | Fitzjarrell | Nov 1999 | A |
5996851 | Dolan et al. | Dec 1999 | A |
5997887 | Ha et al. | Dec 1999 | A |
5997890 | Sine et al. | Dec 1999 | A |
D418708 | Kanfer et al. | Jan 2000 | S |
6022551 | Jampani et al. | Feb 2000 | A |
6024942 | Tanner et al. | Feb 2000 | A |
D422828 | Kanfer et al. | Apr 2000 | S |
6065639 | Maddox et al. | May 2000 | A |
6090395 | Asmus et al. | Jul 2000 | A |
6130253 | Franklin et al. | Oct 2000 | A |
6149925 | Mammone et al. | Nov 2000 | A |
6183766 | Sine et al. | Feb 2001 | B1 |
6217885 | Roder et al. | Apr 2001 | B1 |
6224888 | Vatter et al. | May 2001 | B1 |
6265363 | Viscovitz | Jul 2001 | B1 |
6267976 | Barnhart et al. | Jul 2001 | B1 |
6274124 | Vollhardt | Aug 2001 | B1 |
6309657 | Vatter et al. | Oct 2001 | B2 |
6319958 | Johnson et al. | Nov 2001 | B1 |
6333039 | Fendler et al. | Dec 2001 | B1 |
6344218 | Dodd et al. | Feb 2002 | B1 |
6352701 | Scholz et al. | Mar 2002 | B1 |
6383505 | Kaiser et al. | May 2002 | B1 |
6383997 | McManus | May 2002 | B1 |
6423329 | Sine et al. | Jul 2002 | B1 |
6432430 | Fitzjarrell | Aug 2002 | B1 |
6534069 | Asmus et al. | Mar 2003 | B1 |
6592880 | Jager | Jul 2003 | B1 |
6607737 | Bekele et al. | Aug 2003 | B2 |
6613341 | Motley et al. | Sep 2003 | B2 |
6623744 | Asmus et al. | Sep 2003 | B2 |
6689593 | Millis et al. | Feb 2004 | B2 |
6709647 | Bhakoo et al. | Mar 2004 | B2 |
6723689 | Hoang et al. | Apr 2004 | B1 |
6846846 | Modak et al. | Jan 2005 | B2 |
6939552 | Ansara et al. | Sep 2005 | B2 |
6977082 | Seitz, Jr. et al. | Dec 2005 | B2 |
6979468 | Pollard | Dec 2005 | B1 |
7081246 | Asmus et al. | Jul 2006 | B2 |
7166435 | Rosenbloom | Jan 2007 | B2 |
7199090 | Koivisto et al. | Apr 2007 | B2 |
7465697 | DeAth | Dec 2008 | B1 |
7560422 | Shapiro | Jul 2009 | B2 |
7569530 | Pan et al. | Aug 2009 | B1 |
7612115 | Suzuki et al. | Nov 2009 | B2 |
7651990 | Asmus | Jan 2010 | B2 |
7795196 | Luu et al. | Sep 2010 | B2 |
7803390 | Asmus et al. | Sep 2010 | B2 |
7842725 | Wegner et al. | Nov 2010 | B2 |
7914774 | Meehan | Mar 2011 | B2 |
8058315 | Wegner et al. | Nov 2011 | B2 |
8106094 | Sah et al. | Jan 2012 | B2 |
8119698 | Polonka et al. | Feb 2012 | B2 |
8333954 | Seidling et al. | Dec 2012 | B2 |
8383686 | Wegner et al. | Feb 2013 | B2 |
8530524 | Wegner et al. | Sep 2013 | B2 |
8658701 | Wegner et al. | Feb 2014 | B2 |
8940797 | Wegner et al. | Jan 2015 | B2 |
9414586 | Wegner | Aug 2016 | B2 |
20020022660 | Jampani et al. | Feb 2002 | A1 |
20020168329 | Kini et al. | Nov 2002 | A1 |
20030023550 | Lee | Jan 2003 | A1 |
20030049212 | Robinson et al. | Mar 2003 | A1 |
20030147925 | Sawan et al. | Aug 2003 | A1 |
20030194447 | Scholz et al. | Oct 2003 | A1 |
20030203452 | Li et al. | Oct 2003 | A1 |
20030211066 | Scholz et al. | Nov 2003 | A1 |
20030215418 | Asmus et al. | Nov 2003 | A1 |
20040001797 | Saud et al. | Jan 2004 | A1 |
20040102429 | Modak et al. | May 2004 | A1 |
20040191274 | Grayson et al. | Sep 2004 | A1 |
20040247685 | Modak et al. | Dec 2004 | A1 |
20050053593 | Wang et al. | Mar 2005 | A1 |
20050058673 | Scholz et al. | Mar 2005 | A1 |
20050089539 | Scholz et al. | Apr 2005 | A1 |
20050102266 | Nason et al. | May 2005 | A1 |
20050142079 | Garrison et al. | Jun 2005 | A1 |
20060014750 | O'Donnell et al. | Jan 2006 | A1 |
20060051384 | Scholz et al. | Mar 2006 | A1 |
20060062832 | Lopes | Mar 2006 | A1 |
20060094387 | Darabi | May 2006 | A1 |
20060104911 | Novak | May 2006 | A1 |
20060104919 | Novak | May 2006 | A1 |
20060177511 | Scholz et al. | Aug 2006 | A1 |
20060182690 | Veeger et al. | Aug 2006 | A1 |
20060193745 | Arndt et al. | Aug 2006 | A1 |
20060193789 | Tamarkin et al. | Aug 2006 | A1 |
20060221103 | Takanose et al. | Oct 2006 | A1 |
20060222502 | Hansen et al. | Oct 2006 | A1 |
20060229364 | Hobbs et al. | Oct 2006 | A1 |
20060235798 | Alkove et al. | Oct 2006 | A1 |
20060281663 | Asmus | Dec 2006 | A1 |
20070027055 | Koivisto et al. | Feb 2007 | A1 |
20070065383 | Fernandez de Castro et al. | Mar 2007 | A1 |
20070076125 | Choi et al. | Apr 2007 | A1 |
20070148101 | Snyder et al. | Jun 2007 | A1 |
20070179207 | Fernandez de Castro et al. | Aug 2007 | A1 |
20070184013 | Snyder et al. | Aug 2007 | A1 |
20070184016 | Macinga et al. | Aug 2007 | A1 |
20070185216 | Snyder et al. | Aug 2007 | A1 |
20070190177 | Kling et al. | Aug 2007 | A1 |
20070237807 | Luu et al. | Oct 2007 | A1 |
20070258911 | Fernandez de Castro et al. | Nov 2007 | A1 |
20070274926 | Fuls et al. | Nov 2007 | A1 |
20070274940 | Fuls et al. | Nov 2007 | A1 |
20070275929 | Fuls et al. | Nov 2007 | A1 |
20070280900 | Fox et al. | Dec 2007 | A1 |
20070280901 | Fuls et al. | Dec 2007 | A1 |
20070281039 | DeAth | Dec 2007 | A1 |
20070281999 | Fox et al. | Dec 2007 | A1 |
20080004449 | Yong et al. | Jan 2008 | A1 |
20080026974 | Barnhart et al. | Jan 2008 | A1 |
20080044479 | Stack | Feb 2008 | A1 |
20080095814 | Taylor et al. | Apr 2008 | A1 |
20080108704 | Asmus et al. | May 2008 | A1 |
20080121355 | Pylkki et al. | May 2008 | A1 |
20080138438 | Taylor et al. | Jun 2008 | A1 |
20080139656 | Taylor et al. | Jun 2008 | A1 |
20080142023 | Schmid et al. | Jun 2008 | A1 |
20080145390 | Taylor et al. | Jun 2008 | A1 |
20080199535 | Taylor et al. | Aug 2008 | A1 |
20080200890 | Wood et al. | Aug 2008 | A1 |
20080207767 | Dobos et al. | Aug 2008 | A1 |
20080213198 | Lintner et al. | Sep 2008 | A1 |
20080213595 | Levitt et al. | Sep 2008 | A1 |
20080249187 | Ali et al. | Oct 2008 | A1 |
20080254150 | Rheins et al. | Oct 2008 | A1 |
20080286223 | Fuls et al. | Nov 2008 | A1 |
20080287538 | Scholz et al. | Nov 2008 | A1 |
20090009806 | Matsuda | Jan 2009 | A1 |
20090012174 | Seitz, Jr. et al. | Jan 2009 | A1 |
20090018213 | Snyder et al. | Jan 2009 | A1 |
20090023890 | Monahan et al. | Jan 2009 | A1 |
20090046116 | Davies et al. | Feb 2009 | A1 |
20090095821 | Feriani et al. | Apr 2009 | A1 |
20090104281 | Taylor et al. | Apr 2009 | A1 |
20090117061 | Gross | May 2009 | A1 |
20090191248 | Hoffman et al. | Jul 2009 | A1 |
20090202463 | Pan et al. | Aug 2009 | A1 |
20090214628 | de Rijk | Aug 2009 | A1 |
20090226541 | Scholz et al. | Sep 2009 | A1 |
20090252775 | Arndt et al. | Oct 2009 | A1 |
20090265230 | Plachouras et al. | Oct 2009 | A1 |
20090281021 | Venkataraman et al. | Nov 2009 | A1 |
20090304812 | Staniforth et al. | Dec 2009 | A1 |
20090324661 | Polonka et al. | Dec 2009 | A1 |
20090326076 | Asmus | Dec 2009 | A1 |
20100003198 | Stolmeier et al. | Jan 2010 | A1 |
20100022654 | Asmus et al. | Jan 2010 | A1 |
20100029780 | Grayson et al. | Feb 2010 | A1 |
20100069505 | Veeger et al. | Mar 2010 | A1 |
20100124280 | Chujoh et al. | May 2010 | A1 |
20100160453 | Koivisto et al. | Jun 2010 | A1 |
20100204323 | Theiler et al. | Aug 2010 | A1 |
20100282409 | Hobbs et al. | Nov 2010 | A1 |
20100305211 | Modak et al. | Dec 2010 | A1 |
20100317743 | Macinga et al. | Dec 2010 | A1 |
20100327013 | Asmus | Dec 2010 | A1 |
20100331411 | Asmus | Dec 2010 | A1 |
20100331422 | Asmus et al. | Dec 2010 | A1 |
20110104079 | Snyder et al. | May 2011 | A1 |
20110110869 | Scholz et al. | May 2011 | A1 |
20110144214 | Snyder et al. | Jun 2011 | A1 |
20110224144 | Akil et al. | Sep 2011 | A1 |
20110230395 | Otto et al. | Sep 2011 | A1 |
20110274770 | Scholz et al. | Nov 2011 | A1 |
20120011468 | Zhang | Jan 2012 | A1 |
20120121725 | Gamier et al. | May 2012 | A1 |
20120164087 | Carter | Jun 2012 | A1 |
20120189684 | Buckley et al. | Jul 2012 | A1 |
20120208894 | Kampf et al. | Aug 2012 | A1 |
Number | Date | Country |
---|---|---|
19523320 | Jan 1997 | DE |
0396442 | Nov 1990 | EP |
0849070 | Jun 1998 | EP |
0882446 | Dec 1998 | EP |
1811013 | Jul 2007 | EP |
2181187 | Jun 2008 | EP |
1811013 | Aug 2009 | EP |
2005051341 | Jun 2005 | WO |
2006094387 | Sep 2006 | WO |
2006138111 | Dec 2006 | WO |
2009027867 | Mar 2009 | WO |
Entry |
---|
Berfeld, Wilma F., et al., “Safety Assessment of Alkoxy Polysiloxanes as Used in Cosmetics”, Draft Report for Panel Review, (2014), 235 pages. |
European Patent Office, “Extended European Search Report”, issued in connection to European Application No. 16158741.5, dated May 31, 2016, 10 pages. |
O'Lenick, Tony, “Bis-PEG vs. PEG dimethicone”, Cosmetics and Toiletries, Research, (2007), http://www.cosmeticsandtoiletries.com/research/chemistry/7847427, last accessed on Jul. 28, 2016, 2 pages. |
Brehm-Stecher, Johnson, “Sensitization of Staphylococcus aureus and Escherichia coli to Antibiotics by the Sesquiterpenoids Nerolidol, Farnesol, Bisabolol, and Apritone”, University of Wisconsin-Madison, Antimicrobial Agents and Chemotherapy, vol. 47, No. 10, p. 3357-3360. Dec. 31, 2003. |
Cosmocil (TM) Folder, 5 pages. Jun. 9, 2014. |
Intrinsic Activity of Cosmocil CQ, Avecia, 2 pages. Jun. 9, 2014. |
Morton, H., “The Relationship of concentration and germicidal efficiency of ethyl alcohol”, Annals of the New York Academy of Sciences, vol. 52, pp. 191-196, XP008066591, the whole document. Dec. 31, 1950. |
Schloss Man, M. (Ed.): “The chemistry and manufacture of cosmetics: formulating. vol. 2, Ed. 3”, Allured Pub., USA 277870, XP002390779, p. 237. Dec. 31, 2000. |
Technical Information from BASF for Bisabolol, 8 pages. Nov. 30, 2002. |
Technical Specification for Farnesol, Symrise, 2 pages. Jun. 1, 2004. |
Search Report for co-pending PCT/IB2009/052871 listing relevant art cited by the International Searching Authority. dated Dec. 31, 2009. |
Worldwide Healthcare, Inc., “Material Safety Data Sheet”. Jan. 24, 2007. |
European Patent Office, “Supplementary European Search Report”, issued in connection with International Application PCT/IB2009/052871, 7 pages, dated Feb. 28, 2013. |
Australian Government, Patent Examination Report No. 1, issued in connection with Patent Application 2009275235, 4 pages, dated Oct. 29, 2014. |
Australian Government, Patent Examination Report No. 2, issued in connection with Patent Application 2009275235, 4 pages, dated Feb. 27, 2015. |
Number | Date | Country | |
---|---|---|---|
20160330955 A1 | Nov 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14496468 | Sep 2014 | US |
Child | 15221779 | US | |
Parent | 14084726 | Nov 2013 | US |
Child | 14496468 | US | |
Parent | 13926051 | Jun 2013 | US |
Child | 14084726 | US | |
Parent | 13742996 | Jan 2013 | US |
Child | 13926051 | US | |
Parent | 13223419 | Sep 2011 | US |
Child | 13742996 | US | |
Parent | 12787624 | May 2010 | US |
Child | 13223419 | US | |
Parent | 12179382 | Jul 2008 | US |
Child | 12787624 | US |